CellCarta and Lunit have partnered to integrate Lunit’s Scope AI pathology tools into clinical trial pathology workflows. The collaboration is designed to help sponsors manage biomarker development, image analysis and trial testing using AI-enabled pathology outputs. CellCarta said the partnership combines its global CDx execution services with Lunit’s AI platform, with an emphasis on interoperability and operational readiness. Lunit said adoption at scale depends on fitting into real trial workflows rather than building AI layers only for document-based processing. The firms are assessing pilot opportunities across trial operations and AI image analysis, with plans to expand the agreement as additional use cases are validated. The deal follows earlier movement by CellCarta to incorporate Lunit solutions more broadly. For biopharma, the near-term impact is faster pathology evidence generation and potentially more consistent biomarker scoring—assuming regulators and sponsors can integrate outputs into end-to-end study evidence packages.